US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022
Juan Carlos C. Montoy, Ralph C. Wang, Allison R. Coker, Craig G. Smollin, B. Anderson
Journal of the American College of Emergency Physicians Open August 30, 2025 DOI: 10.1016/j.acepjo.2025.100231 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Population | Poison control center encounters |
| Duration | 2013 to 2022 |
| Topics | Psilocybin |
| Keywords | Center category theory Poison control center Hallucinogen Environmental health |
| Citations | 3 |
| Key findings | Psilocybin-related poison control encounters increased threefold from 2013 to 2022, with most of the increase occurring after 2019. |
Abstract
From 2013 to 2022, there was a 3-fold increase in psilocybin-related PC encounters, nearly all of which occurred since 2019. A similar pattern was not observed with other substances. Although the number of encounters remains low, this trend could continue as psilocybin use increases.
Comparable studies
Other observational and cohort studies on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression | 2017 | Observational cohort | n = 19 |
| Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels Healthy volunteers | 2019 | Observational cohort | n = 8 |
| Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans | 2017 | Observational study | |
| Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. USA adult respondents from the National Survey on Drug Use and Health (2008-2012) | 2015 | Observational cohort | n = 190,000 |
| Prediction of Psilocybin Response in Healthy Volunteers Healthy volunteers | 2012 | Observational cohort | n = 409 |
Citations in the library
Cited by 3
- Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA SAIMSARA Journal June 15, 2026
- Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health. Drug and Alcohol Dependence May 1, 2026
- Level of Preparedness to Use Psilocybin Among Individuals Seeking Psychedelic Risk Reduction: A retrospective study of a pilot psychiatric consultation service medRxiv August 19, 2026
Cites 10
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- The pharmacology of psilocybin Addiction Biology October 1, 2002
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology June 5, 2018
- Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology February 2, 2022
- Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry April 5, 2016
and 5 more in the library